Примери за използване на Day subcutaneously на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Placebo once a day subcutaneously n(%).
Reproductive and developmental toxicity studies evaluating teduglutide have been carried out in rats and rabbits at doses of 0, 2, 10 and50 mg/kg/day subcutaneously.
The recommended starting dose is 1.2 MIU(12 μg)/kg/day subcutaneously as a single dose or in.
Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2-3 days in dogs for up to 52 weeks was also well tolerated.
Enoxaparin sodium 4,000 IU(40 mg) once a day subcutaneously n(%).
When given at a dose of 4,000 IU(40 mg) once a day subcutaneously, enoxaparin sodium significantly reduced the incidence of VTE as compared to placebo.
Enoxaparin sodium 100 IU/kg(1 mg/kg)twice a day subcutaneously n(%).
Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2-3 days in dogs for up to 52 weeks was also well tolerated.
Enoxaparin sodium 150 IU/kg(1.5 mg/kg)once a day subcutaneously n(%).
In two published research studies,rabbits exposed to ciclosporin in utero(10 mg/kg/day subcutaneously) demonstrated reduced numbers of nephrons, renal hypertrophy, systemic hypertension, and progressive renal insufficiency up to 35 weeks of age.
For PBPC mobilisation in normal donors,filgrastim should be administered at 1.0 MIU(10 μ g)/ kg/ day subcutaneously for 4 to 5 consecutive days. .
Reproduction studies carried out with ganirelix at doses of 0.1 to 10 μ g/ kg/ day subcutaneously in the rat and 0.1 to 50 μ g/ kg/ day subcutaneously in the rabbit showed increased litter resorption in the highest dose groups.
In a second double-blind study, 262 patients without VTE disease and undergoing hip replacement surgery initially treated, while hospitalized, with enoxaparin sodium 4,000 IU(40 mg)subcutaneously were randomized to a post-discharge regimen of either enoxaparin sodium 4,000 IU(40 mg)(n=131) once a day subcutaneously or to placebo(n=131) for 3 weeks.
The recommended starting dose is 1.2 MIU(12 μg)/kg/day subcutaneously as a single dose or in divided doses.
Prevention of venous thromboembolic disease associated with surgery Extended prophylaxis of VTE following orthopaedic surgery In a double blind study of extended prophylaxis for patients undergoing hip replacement surgery, 179 patients with no venous thromboembolic disease initially treated, while hospitalized, with enoxaparin sodium 4,000 IU(40 mg) subcutaneously, were randomized to a post-discharge regimen of either enoxaparin sodium 4,000 IU(40 mg)(n=90) once a day subcutaneously or to placebo(n=89) for 3 weeks.
Congenital neutropenia The recommended starting dose is 1.2 MIU(12 μ g)/ kg/ day subcutaneously as a single dose or in divided doses.
Reproduction studies carried out with ganirelix at doses of 0.1 to 10g/kg/day subcutaneously in the rat and 0.1 to 50g/kg/day subcutaneously in the rabbit showed increased litter resorption in the highest dose groups.
Idiopathic or cyclic neutropenia The recommended starting dose is 0.5 MIU(5 μ g)/ kg/ day subcutaneously as a single dose or in divided doses.
In a double blind multicentre, parallel group study, enoxaparin sodium 2,000 IU(20 mg) or4,000 IU(40 mg) once a day subcutaneously was compared to placebo in the prophylaxis of DVT in medical patients with severely restricted mobility during acute illness(defined as walking distance of< 10 meters for≤ 3 days). .
Treatment of deep vein thrombosis with or without pulmonary embolism In a multicentre, parallel group study, 900 patients with acute lower extremity DVT with or without PE were randomized to an inpatient(hospital) treatment of either(i)enoxaparin sodium 150 IU/kg(1.5 mg/kg) once a day subcutaneously,(ii) enoxaparin sodium 100 IU/kg(1 mg/kg) every 12 hours subcutaneously, or(iii) heparin intravenous bolus(5,000 IU) followed by a continuous infusion(administered to achieve an aPTT of 55 to 85 seconds).
In the IFN arm,patients were treated with a target dose of IFN of 5 MIU/ m2/ day subcutaneously in combination with subcutaneous Ara-C 20 mg/ m2/ day for 10 days/ month.
The solution for injection should be administered subcutaneously each day.
Leuprolide is injected subcutaneously once a day.
The dose in both studies was 0.043 mg/kg/day, administered subcutaneously(s.c.).
Maintenance dose: 1.2 mg subcutaneously once a day;
Maintenance dose: Inject 1.2 mg subcutaneously once a day;
It should be administered subcutaneously twice a day after meals.
The reconstituted solution is to be injected subcutaneously every other day.
Initial dose: 0.6 mg subcutaneously once a day for 1 week;
Please administer the prescribed dose of NutropinAq solution for injection subcutaneously each day and change the site of injection each time.